Lupin's Nagpur Oral Solid Dosage facility gets 2 observations from USFDA

U.S. FDA inspected Lupin's Nagpur Oral Solid Dosage Facility from July 3 to July 11, 2023. The inspection closed with issuance of a Form-483 with two observations.

The company is confident of addressing the observations raised, and will work with the U.S. FDA to resolve them at the earliest. The company said it would uphold quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all its facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 940.25 as compared to the previous close of Rs. 912.90. The total number of shares traded during the day was 60130 in over 3122 trades.

The stock hit an intraday high of Rs. 943.10 and intraday low of 915.60. The net turnover during the day was Rs. 55957315.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Nagpur OralSolidDosageFacility USFDA Inspection Form483 2Observations